Research progress on HER2-specific chimeric antigen receptor T cells for immunotherapy of solid tumors
Human epidermal growth factor receptor 2 (HER2) is highly expressed in various solid tumors, and its abnormal activation is closely associated with poor tumor prognosis, establishing it as a prominent target in contemporary research. The successful clinical treatment of multiple HER2-positive tumors...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1514994/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Human epidermal growth factor receptor 2 (HER2) is highly expressed in various solid tumors, and its abnormal activation is closely associated with poor tumor prognosis, establishing it as a prominent target in contemporary research. The successful clinical treatment of multiple HER2-positive tumors with HER2 antibodies has prompted researchers to design chimeric antigen receptor T (CAR-T) cells targeting HER2 for solid tumor immunotherapy. To date, the development of CAR structures has progressed to the fifth generation, with most HER2-CAR-T cell structures being modified based on the second-generation CAR architecture. This review will delineate the structure and cytotoxic mechanism of HER2-CAR-T cells, elucidate the difficulties and optimization strategies for HER2-CAR-T cell therapy, and summarize recent clinical applications and advancements. |
|---|---|
| ISSN: | 1664-3224 |